Successful treatment of Candida krusei infection with caspofungin acetate: A new antifungal agent
- 1 May 2003
- journal article
- case report
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 31 (5) , 1577-1578
- https://doi.org/10.1097/01.ccm.0000063145.15336.31
Abstract
Systemic fungal infections have high mortality, and therapy is often toxic. Caspofungin acetate, a new antifungal agent with minimal toxicity, may provide a better alternative to typical therapy for Candida krusei. Case report. Multidisciplinary intensive care unit (ICU) of a community teaching hospital. A 22-yr-old male with acute lymphoblastic leukemia and Candida krusei fungemia failed therapy with fluconazole and amphotericin B. Caspofungin acetate given intravenously as a 70-mg loading dose, followed up by 50 mg daily along with standard ICU care. Survival without toxicity from therapy. Efficacy of caspofungin acetate in a patient with life-threatening Candida Krusei infection.Keywords
This publication has 3 references indexed in Scilit:
- In Vitro Activity of Caspofungin (MK-0991) against Candida albicans Clinical Isolates Displaying Different Mechanisms of Azole ResistanceJournal of Clinical Microbiology, 2002
- Antifungal Resistance Among Candida SpeciesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
- In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)Antimicrobial Agents and Chemotherapy, 1997